Underestimate biosimilars at your peril, experts warn

A panel of analysts and investors have told a conference that the threat of biosimilars to the reference drug manufacturers should not be underestimated.

The panellists at The Financial Times Pharmaceutical and Biotechnology Conference 2017 were discussing how markets view the future for the industry.

They singled out some of the big-selling biologics that are either already facing competition in major markets, or are fighting to hold off other market entrants.